CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
With Canada set to drastically increase its defence spend in 2026, Calian is expected to see a major boon of new contracts.
Cathie Wood’s ARK Invest executed a busy week of portfolio adjustments across its ETFs, with several high-conviction ...
Desjardins analyst Brent Sadler published his year-ahead report for domestic power and utilities stocks, ...
Given these factors, my favorite index ETF to outperform in 2026 is the Vanguard Mega Cap Growth ETF as it's one of the most ...
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...
The Vanguard Growth ETF holds large positions in tech giants like Nvidia, with a healthy splash of diversification.
From 1960s computers to AI, how the stock market's 10% average return was uncovered—and why it still guides investors today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback